

Vaccination of Respiratory Infections

? Vaccination of Respiratory Infections ? COMPLETE REVISION

? 1. Tuberculosis (TB)

Vaccine

- BCG (Bacillus Calmette–Guérin)
-

Type

- Live attenuated vaccine
-

Mechanism of Action (MOA)

- Induces cell-mediated immunity (T-cell response)
 - Prevents severe forms (meningitis, miliary TB)
-

Age Group

- At birth (UIP schedule)
-

Dose & Route

- 0.05 mL (infant), 0.1 mL (older child)
 - Intradermal (left upper arm)
-

Storage / Stability

- Store at 2–8°C
 - Light-sensitive
 - Reconstituted vaccine ? use within 4–6 hours
-

Effectiveness

- Protects against severe childhood TB
 - Variable efficacy for pulmonary TB
-

? 2. Diphtheria

Vaccine

- DPT / Pentavalent vaccine
-

Type

- Toxoid vaccine
-

MOA

- Induces antitoxin antibodies
-

- Neutralizes diphtheria toxin
-

Age Group

- 6, 10, 14 weeks
 - Booster ? 16–24 months, 5 years
-

Dose & Route

- 0.5 mL IM
-

Storage

- 2–8°C
 - Do NOT freeze
-

Effectiveness

- Highly effective
 - Requires **booster doses**
-

? 3. Pertussis

Vaccine

- DPT (whole-cell or acellular)
-

Type

- Killed (whole-cell) / Subunit (acellular)
-

MOA

- Induces antibodies against:
 - Pertussis toxin
 - Adhesion factors
-

Age Group

- Same as Diphtheria (UIP schedule)
-

Dose & Route

- 0.5 mL IM
-

Storage

- 2–8°C
-

Effectiveness

- Good protection
 - Immunity **wanes over time** ? boosters needed
-

? 4. Measles

Vaccine

- Measles / MR / MMR
-

Type

- Live attenuated vaccine
-

MOA

- Induces **humoral + cellular immunity**
-

Age Group

- **9 months** (first dose)
 - Booster later
-

Dose & Route

- **0.5 mL SC**
-

Storage

- **2–8°C**
 - Highly **heat & light sensitive**
 - Reconstituted ? use within **4–6 hours**
-

Effectiveness

- ~95% effective after 1 dose
- Nearly 100% after booster

? 5. Influenza

Vaccine

- Influenza vaccine (Trivalent/Quadrivalent)

Type

- Killed (inactivated)

MOA

- Induces antibodies against **hemagglutinin (HA)**

Age Group

- >6 months of age
- Annual vaccination

Dose & Route

- 0.5 mL IM

Storage

- 2–8°C
 - Do NOT freeze
-

Effectiveness

- Variable (~40–60%)
 - Depends on strain match
-

? 6. COVID-19

Vaccine

- Examples:
 - Covishield
 - Covaxin
 - mRNA vaccines
-

Type

- **Viral vector / Inactivated / mRNA**
-

MOA

- Induces antibodies against **spike protein**
 - Activates **cellular immunity**
-

Age Group

- Adults & children (as per guidelines)

Dose & Route

- 0.5 mL IM

Storage

- 2–8°C (most vaccines)
- mRNA vaccines may require **ultra-cold storage**

Effectiveness

- Prevents **severe disease & mortality**
- Booster doses required

? 7. Pneumococcal Vaccine

Vaccine

- PCV (Pneumococcal Conjugate Vaccine)

Type

- Conjugate vaccine

MOA

- Converts T-independent ? T-dependent response
 - Strong immunity in children
-

Age Group

- Infants (UIP)
-

Dose & Route

- 0.5 mL IM
-

Storage

- 2-8°C
-

Effectiveness

- Prevents:
 - Pneumonia
 - Meningitis
-

? 8. Rotavirus (Respiratory relevance via child mortality overlap)

Type

- Live attenuated (oral)

MOA

- Induces mucosal immunity

Dose

- Oral drops

Storage

- 2–8°C

? SUPER REVISION TABLE (VERY IMPORTANT)

DISEASE	VACCINE TYPE	ROUTE	AGE	KEY POINT
TB	Live	ID	Birth	Severe TB prevention
Diphtheria	Toxoid	IM	6–14 weeks	Antitoxin
Pertussis	Killed/Subunit	IM	6–14 weeks	Whooping cough
Measles	Live	SC	9 months	Highly contagious
Influenza	Killed	IM	>6 months	Annual vaccine
COVID-19	mRNA/Inactivated	IM	All age groups	Spike protein

DISEASE	VACCINE TYPE	ROUTE	AGE	KEY POINT
Pneumococcal	Conjugate	IM	Infants	Severe infections

? ULTRA HIGH-YIELD EXAM POINTS

- Live vaccines ? **strong immunity, contraindicated in pregnancy**
- Toxoid ? **diphtheria, tetanus**
- Conjugate ? **better in infants**
- BCG ? **ID route (unique)**
- OPV ? **oral (unique)**
- Cold chain ? **2–8°C (universal rule)**